SEC CRD #802-132677
We invest in biotechnology companies that are developing treatments for patients suffering from life-threatening antimicrobial-resistant infections. The industry-led AMR Action Fund organized by IFPMA is a groundbreaking USD 1 billion initiative that aims to bring 2-4 new antibiotics to patients by 2030. The investment in Swiss drugmaker BioVersys AG will help fund the development of the company's novel antibiotic candidates.
DAVID C. HELLMUTH
GENERAL COUNSEL AND CHIEF OPERATING OFFICER
📞 41 79 506 5705
🔒 Sign up for free to view key contact information
Sign up free →This profile has not yet been verified by the firm. Information may be incomplete or outdated. Claim this profile to take control of your listing.
Location
BASEL, BASEL-STADT
Claim this profile to complete your information, set investment criteria, and start receiving curated deal flow from sponsors on DEALITHIC.